InvestSMART

Nexalis Therapeutics Ltd (ASX:NX1)

ALERT: Price-sensitive ASX Announcement for NX1
Current share price for NX1 : $0.009 -0.002 (-18.18%)+
Announcement
Release
31 Jul 2026 1:06PM
Price at Release
$0.011
Full Release
download
Summary
Nexalis Therapeutics Ltd, an Australian clinical stage drug development company, reported on its activities for the quarter ended June 30, 2026. Significant developments included the completion of Phase 1 dosing of IRX-616a for panic disorder, with no serious adverse events, and advancements in the IRX-211 Phase 2 trials for breakthrough cancer pain, despite recruitment challenges. The company is also progressing the SRX-25 program for treatment-resistant depression. However, Nexalis faced a setback as the Linlithgow Family Office canceled its funding commitment, prompting the company to seek alternative funding partners. Despite this, Nexalis continues to plan for Phase 2 trials for its drug candidates, focusing on efficient clinical development and potential FDA approval using rapid regulatory pathways.
Key Points
  • IRX-616a Phase 1 dosing completed with no serious adverse events.
  • IRX-211 Phase 2 trial site evaluations expanded to new locations.
  • SRX-25 development planning for treatment-resistant depression advanced.
  • Linlithgow Family Office funding facility permanently canceled.
  • Nexalis seeks new funding partners to support clinical trials.
  • Net cash surplus of $648k from operating activities reported.
  • Company aims for U.S. FDA approval using rapid regulatory pathways.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.